Sacubitril/Valsartan may Improve Diabetic Cardiomyopathy via Immunomodulation of Inflammation: Study
A recent study published in Cardiovascular Diabetology reveals that Sacubitril/Valsartan, a combination of a neprilysin inhibitor and an angiotensin receptor blocker, may improve diabetic cardiomyopathy (DbCM) by modulating inflammatory pathways.
This dual-action medication, known for its role in heart failure management, demonstrates potential in addressing the underlying inflammation associated with DbCM.
In both clinical and experimental settings, Sacubitril/Valsartan effectively reduced plasma neprilysin activity. In diabetic patients with pre-clinical heart failure with preserved ejection fraction (HFpEF), higher baseline neprilysin activity correlated with worsening cardiac performance over 18 months.
Treatment with Sacubitril/Valsartan improved diastolic dysfunction and pathological remodeling in DbCM mice, effects not observed with Valsartan alone.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.